TB-500 (Thymosin Beta-4)
🔬 Overview
TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4, which is present in virtually all human and animal cells. It plays a critical role in the polymerisation of actin — one of the primary proteins responsible for cell structure, movement, and repair.
Its key mechanism involves binding to actin monomers (G-actin), which facilitates cellular migration, wound healing, and the formation of new blood vessels. TB-500 regulates cell-building proteins that promote tissue healing throughout the body, earning its classification as a systemic healing agent.
Unlike BPC-157, which tends to exert more localised effects, TB-500 operates systemically — making it particularly useful for widespread tissue damage, chronic injuries, and cardiovascular research applications.
💉 Dosing Protocol
| Phase | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Loading (Low) | 4 mg | 2x per week | 4–6 weeks | Conservative research start |
| Loading (Standard) | 5–8 mg | 2x per week | 4–6 weeks | Most common protocol |
| Maintenance (Low) | 2–2.5 mg | 2x per week | Ongoing | After loading phase |
| Maintenance (Standard) | 5 mg | Once per week | Ongoing | Single weekly dose viable due to long half-life |
⚗️ Reconstitution Instructions
- Allow 10mg TB-500 vial and BAC water to reach room temperature
- Wipe both vial tops with alcohol swab, allow to dry
- Draw 2ml BAC water into sterile syringe
- Inject slowly into TB-500 vial down the glass wall — do not agitate
- Gently roll vial between palms — do not shake
- Solution should be clear. Resulting concentration: 5000 mcg/ml
- Refrigerate at 2–8°C. Use within 30 days.
📍 Injection Sites
TB-500 is administered subcutaneously or intramuscularly. Given its systemic mechanism of action, injection site does not significantly alter efficacy — subcutaneous abdominal injection is standard for convenience. Rotate sites with each administration.
🔗 Stack Compatibility
The BPC-157 + TB-500 combination is the most researched healing stack. BPC-157 addresses acute localised repair while TB-500 provides systemic support — the two mechanisms are complementary rather than redundant.
📚 Research Notes
Animal studies have demonstrated TB-500 efficacy in cardiac repair following myocardial infarction, accelerated wound healing, corneal repair, and improvement of flexibility in connective tissue. The peptide has been studied extensively in equine sports medicine.
TB-500 has shown cardioprotective effects in multiple animal models, promoting cardiac progenitor cell migration and reducing infarct size. It is also being investigated for its neurological repair potential.
⚠️ Disclaimer
TB-500 is a research chemical not approved for human use. All information is for research purposes only. This is not medical advice.